文献速递脊柱关节炎

塞妥珠单抗聚乙二醇治疗非放射学中轴型脊柱关节炎52周随机对照试验

A Fifty-Two-Week, Randomized, Placebo-Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis.
PubMed 文献 · Arthritis Rheumatol · 2019-05-28

这项为期52周的随机双盲安慰剂对照研究纳入317例有客观炎症征象的活动性非放射学中轴型脊柱关节炎患者,比较塞妥珠单抗(CZP)联合非生物制剂背景用药与安慰剂联合背景用药的疗效。结果显示第52周CZP组ASDAS主要改善率达47.2%,显著高于安慰剂组的7.0%(P<0.0001),表明在背景用药基础上加用CZP优于加用安慰剂。

要点

  • 活动性非放射学中轴型SpA患者加用CZP后52周ASDAS-MI达47.2%,显著优于安慰剂组的7.0%。
  • 安慰剂组60.8%患者在第52周前转为开放标签治疗,CZP组仅12.6%。
  • 不采用生物制剂治疗的非放射学中轴型SpA患者达到缓解者少见,提示需要超越非生物制剂治疗。

核心结论

  • 在活动性非放射学中轴型SpA患者中,背景用药加用CZP优于加用安慰剂。
  • 不采用生物制剂治疗的非放射学中轴型SpA患者达到缓解者少见,提示需要超越非生物制剂治疗。

研究设计与样本

  • 正在进行的平行组双盲研究,从澳大利亚、欧洲、北美和中国台湾的80个中心招募活动性非放射学中轴型SpA成人患者。
  • 患者按1:1随机接受安慰剂或CZP(第0、2、4周400mg,随后每2周200mg)联合非生物制剂背景用药。
  • 共317例患者随机分组:安慰剂联合背景用药组158例,CZP联合背景用药组159例。
  • 主要终点为第52周ASDAS主要改善(ASDAS-MI)的患者比例。

主要发现

  • 第52周CZP联合背景用药组ASDAS-MI达标率为47.2%(75/159),显著高于安慰剂联合背景用药组的7.0%(11/158)(P<0.0001)。
  • 安慰剂联合背景用药组60.8%(96/158)在第52周前转为开放标签治疗,CZP联合背景用药组为12.6%(20/159)。

关键数值与推荐

  • ASDAS主要改善(MI)定义为ASDAS评分较基线下降≥2.0分或达到最低可能评分0.6。
  • CZP给药方案:第0、2、4周400mg,随后每2周200mg。
  • 主要终点第52周ASDAS-MI达标率组间比较P<0.0001。

临床怎么用

  • 对于有客观炎症征象的活动性非放射学中轴型SpA患者,可考虑在非生物制剂背景用药基础上加用CZP以改善疾病活动度。
  • 不采用生物制剂治疗时达到缓解者少见,临床应识别需要升级至生物制剂治疗的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The natural history of nonradiographic axial spondyloarthritis (SpA) is incompletely characterized, and there are concerns that nonsteroidal antiinflammatory drugs provide inadequate disease control in patients with active disease. This study was undertaken to investigate the effects of certolizumab pegol (CZP), an anti-tumor necrosis factor treatment, in patients with nonradiographic axial SpA with objective signs of inflammation. METHODS: In this ongoing parallel-group double-blind study, adults with active disease were recruited from 80 centers in Australia, Europe, North America, and Taiwan, and were randomized 1:1 to receive placebo or CZP (400 mg at weeks 0, 2, and 4, followed by 200 mg every 2 weeks) in addition to nonbiologic background medication (NBBM). Switching to open-label CZP (or other biologic) or making background medication changes was permitted at any point during the trial, although changes before week 12 were discouraged. The primary end point was the proportion of patients achieving major improvement (MI) (i.e., a ≥2.0-point decrease in the score from baseline or achievement of the lowest possible score [0.6]) in the Ankylosing Spondylitis Disease Activity Score (ASDAS) at week 52. RESULTS: A total of 317 patients were randomized to receive placebo plus NBBM (n = 158) or CZP plus NBBM (n = 159). ASDAS-MI at week 52 was achieved in 47.2% (75 of 159) of CZP plus NBBM patients, which was significantly greater (P < 0.0001) than the 7.0% (11 of 158) of placebo plus NBBM patients in whom ASDAS-MI was achieved. Of the placebo plus NBBM patients, 60.8% (96 of 158) switched to open-label treatment before week 52 compared to 12.6% (20 of 159) of the CZP plus NBBM patients. CONCLUSION: Adding CZP to background medication is superior to adding placebo in patients with active nonradiographic axial SpA. These results indicate that remission in nonradiographic axial SpA treated without biologics occurs infrequently, demonstrating the need for treatment beyond nonbiologic therapy.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Deodhar A, Gensler LS, Kay J, et al. A Fifty-Two-Week, Randomized, Placebo-Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 2019. PMID: 30848558. doi:10.1002/art.40866

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。